REGN : Analysis & Opinions

  1. Drugs Delayed By Regeneron, Sanofi Plant (REGN, SNY)

    December 1, 2016
    Two potential blockbuster drugs being developed by Regeneron and Sanofi may be delayed by deficiencies at Sanofi's manufacturing ...
  2. Regeneron Sarilumab Drug Tops Humira (REGN, SNY)

    November 21, 2016
    Regeneron and Sanofi said their rheumatoid arthritis drug sarilumab outperformed Humira in a recent late-stage study.
  3. Soros 13F Points to More Than Just Emerging Markets

    November 15, 2016
    Soros Fund Management's 13F for Q3 indicates new positions in several energy comapnies, call options for Bank of America, ...
  4. Regeneron 3Q Net $265M, or $2.27 a Share (REGN)

    November 5, 2016
    Regeneron's 3Q earnings beat street expectations, but revenue fell below analyst estimates.
  5. Pfizer Scraps New Cholesterol Drug (PFE, AMGN)

    November 2, 2016
    Pfizer will take a 4-cent-a-share charge in its 4Q earnings after scrapping its new cholesterol drug.
  6. Pricey Cholesterol Drugs Lose Favor (AMGN, REGN)

    October 31, 2016
    Expensive new cholesterol drugs haven't been selling well, and that's worrying some major drug companies.
  7. Regeneron, Sanofi Drug Hits FDA Snag (REGN, SNY)

    October 30, 2016
    The FDA delayed approval of a competitor drug to Humira being developed by Regeneron and Sanofi due to manufacturing deficiencies.
  8. FDA Holds Regeneron, Teva Pain Study (REGN, TEVA)

    October 18, 2016
    The FDA put Regeneron and Teva's joint study for the pain drug fasinumab on clinical hold, citing safety concerns.
  9. Regeneron, Ocular to Develop Eye Drug (REGN, OCUL)

    October 13, 2016
    Regeneron Pharmaceuticals and Ocular Therapeutix entered a $315 million deal to develop a sustained-release version of the ...
  10. Do High Drug Prices Result in Better Stock Returns? (GILD, REGN)

    October 6, 2016
    We examine the past performance of stock returns of companies which have raised the prices of their drugs the most and the ...
  11. Regeneron, Sanofi Report Drug Results (REGN, SNY)

    October 3, 2016
    Positive results from a Phase III study of the high-cost drug add to high-revenue prospects for Regeneron in the future.
  12. Regeneron Drug Fails in Combination Trial (REGN)

    October 3, 2016
    Regeneron is vulnerable to rivals after failure of its $2 billion blockbuster drug, Eylea, in combination with a new treatment ...
  13. Regeneron Win Review for Dermatitis Drug (REGN)

    September 26, 2016
    The company's drug, which treats a moderate-to-severe form of dermatitis, may be on track for commercial success
  14. Regeneron to Collaborate With Teva for Fasinumab Drug (REGN, ...

    September 20, 2016
    Regeneron will get a global commercialization opportunity with Teva for its innovative chronic pain drug having a large global ...
  15. Tesla Tops Forbes' 2016 List of Most Innovative Companies (TSLA, ...

    August 25, 2016
    Forbes has released its sixth annual "World’s Most Innovative Companies" and Tesla tops the list.
  16. STEM Contest Names Regeneron as Sponsor (REGN, INTC)

    May 26, 2016
    Following Intel's surprising decision to back out of its sponsorship of the Science Talent Search, the STEM contest gets ...
  17. Technology ETFs to Date 2016 Performance Review (XLK, VOX)

    April 27, 2016
    Exercise caution before buying shares of a biotech ETF based on a belief that the biotech sector will follow the broader ...
  18. The 3 Largest Health Care ETFs (XLV, IBB)

    April 25, 2016
    Find out which exchange-traded funds (ETFs) are the largest in terms of total assets under management (AUM) in the health ...
  19. 5 Punished Stocks: Are They Bargains? (ENDP,VRTX)

    March 31, 2016
    These five stocks have been slammed recently. Does this mean they are now bargains?
  20. Portfolio Trends in 2016 (PRHSX)

    March 23, 2016
    Discover how the T. Rowe Price Health Sciences Fund is positioned in 2016, and learn what trends in the portfolio may help ...
  21. (IBB) iShares NASDAQ Biotech SPDR ETF: Top 5 Holdings

    March 16, 2016
    Take a close look at the strong fundamentals underlying the top five holdings of the iShares NASDAQBiotechnology ETF as it ...
  22. Is Amgen About to Enter a Battle Over Billions? (AMGN, REGN)

    June 15, 2015
    The Food and Drug Administration's key advisory committee has given the thumbs-up to two new drugs belonging to an entirely ...
  23. Amgen Gets 1 Step Closer to Another Blockbuster (AMGN, REGN)

    May 26, 2015
    A key European advisory committee has just thrown its support behind approval for Amgen's (NASDAQ: AMGN) Repatha, a new ...
  24. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  25. Market Wrap: Stocks End Flat, but Tesla Shares Sag After Hours

    November 5, 2013
    Stocks ended Tuesday basically flat, as investors started to focus on economic realities. But the market could see some ...
Trading Center